
FDA Approves Second OTC Naloxone Nasal Spray for Opioid Overdose
The U.S. FDA has approved RiVive, a 3mg naloxone hydrochloride nasal spray, for over-the-counter use in the emergency treatment of known or suspected opioid overdose. This is the second nonprescription naloxone product approved by the FDA, aimed at increasing consumer access to naloxone without a prescription. The availability and price of RiVive will be determined by the manufacturer. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. The FDA has been prioritizing access to naloxone products and encourages other manufacturers to develop nonprescription options.
